Increasing Use of Dupilumab and Decreasing Use of Patch Testing in Medicare Patients from 2017 to 2022: A Claims Database Study

Abstract

Get full access to this article

View all access options for this article.

References

Raffi

, Suresh

, Botto

, et al. The impact of dupilumab on patch testing and the prevalence of co-morbid allergic contact dermatitis in recalcitrant atopic dermatitis: A retrospective chart review. J Am Acad Dermatol. 2020; 82(1):132–138; doi: 10.1016/j.jaad.2019.09.028

Medicare Part D Prescribers—by Provider and Drug. Centers for Medicare & Medicaid Services. Available from: https://data.cms.gov/provider-summary-by-type-of-service/medicare-part-d-prescribers/medicare-part-d-prescribers-by-provider-and-drug [Last accessed: April 12, 2024].

Physician/Supplier Procedure Summary. Centers for Medicare & Medicaid Services Data. 2023. Available from: https://data.cms.gov/summary-statistics-on-use-and-payments/physiciansupplier-procedure-summary [Last accessed: April 12, 2024].

Bai

, Murase

, Botto

, et al. Clear, patch, avoid, treat as a diagnostic and therapeutic strategy for management of recalcitrant adult eczematous dermatitis. Dermatitis. 2023; 34(4):343–346.

Jelousi

, Murase

, Bai

, et al. First, do no harm: The urgent need for comprehensive clinical guidelines for diagnostic testing of recalcitrant “atopic dermatitis. J Am Acad Dermatol. 2022; 87(6):e243–e244.